In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue Therapeutics (DBT), which specialises in cancer therapies. The transaction – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results